ArcticZymes Technologies
ArcticZymes Technologies ASA is a Norwegian life science company developing cold-adapted enzymes for molecular diagnostics, RNA therapeutics, and synthetic biology. The company discovers, manufactures, and markets marine-derived enzymes including Cod UNG, SAN, and Salt Active Nuclease, utilized to eliminate DNA contamination and facilitate nucleic acid workflows. Main revenue drivers consist of B2B commercial sales of enzyme reagents and custom formulation fees billed to biopharmaceutical and diagnostic firms. ArcticZymes Technologies serves molecular diagnostic developers, vaccine manufacturers, cell and gene therapy companies, and academic research institutions in North America, Europe, and Asia. The company holds a specialized market position in cold-adapted enzyme development for life science applications. Headquartered in Tromso, Norway, it is listed on Oslo Bors.
3 of the funds FundTelligence covers report a position in ArcticZymes Technologies.
- Legal name
- ArcticZymes Technologies ASA
- Sector
- Health Care
- Country
- Norway
- Funds holding it
- 3
Funds holding ArcticZymes Technologies
- Schroder ISF Nordic Micro Cap — Schroders · 1.43 % (full portfolio disclosed, June 2026)
- Carnegie Small & Micro Cap — Carnegie · 0.54 % (full portfolio disclosed, June 2026)
- Storebrand Indeks Norge — Storebrand · 0.01 % (full portfolio disclosed, October 2026)